Paget's Disease of Bone

  1. Overview
  2. Epidemiology and Prevalence
  3. Pathophysiology — Disordered Bone Remodeling
  4. Genetics and Etiology
  5. Anatomical Sites
  6. Clinical Presentation
  7. Skull and Neurological Complications
  8. Skeletal Complications and Osteosarcoma
  9. Laboratory and Imaging Diagnosis
  10. Treatment — Bisphosphonates
  11. Key Research Papers
  12. PubMed Research Searches
  13. Connections
  14. Featured Videos

Overview

Paget's disease of bone (PDB) is a focal metabolic bone disease characterized by profoundly disordered bone remodeling. It is the second most common metabolic bone disease after osteoporosis, affecting a meaningful proportion of older adults in certain geographic regions. The disease was named after the British surgeon Sir James Paget, who first described it in 1877 under the term osteitis deformans — inflammatory disease of bone with deformity — though we now understand it is not primarily inflammatory in nature.

In Paget's disease, the normal, tightly regulated cycle of bone resorption followed by new bone formation breaks down at one or more discrete skeletal sites. Osteoclasts — the cells responsible for resorbing old bone — become dramatically overactive and abnormally large. In response, osteoblasts lay down new bone at an accelerated rate, but the newly formed bone is architecturally disorganized, structurally weak, and prone to deformity and fracture despite being physically enlarged.

The disease most commonly affects people over 55 years of age and follows a slowly progressive course, often remaining clinically silent for many years or even decades. In the United Kingdom, Australia, and New Zealand, prevalence in those over 55 approaches 1–2%. It is considerably less common in North America, Asia, and Africa. Notably, the incidence of PDB has declined substantially over the past three decades in many countries, an observation with important implications for understanding its cause.

Although most patients with PDB never develop significant symptoms, a minority experience considerable morbidity including bone pain, deformity, hearing loss, fractures, secondary arthritis, neurological complications, and, rarely, malignant transformation. Understanding who to treat, when to treat, and how to monitor is central to modern management.

Back to Table of Contents

Epidemiology and Prevalence

Paget's disease shows a striking geographic distribution that remains incompletely explained. The highest prevalence rates are found in the United Kingdom (particularly Lancashire and Yorkshire), Australia, New Zealand, and parts of western Europe, especially France and Spain. Rates in North America are intermediate, and the disease is rare in Scandinavia, Asia, and sub-Saharan Africa. This geographic clustering suggests both genetic and environmental contributions — a population's ancestral origins influence risk even when individuals migrate to new regions.

Age is the strongest non-genetic risk factor. PDB is rare before age 40, becomes detectable in radiological surveys from age 40–55, and reaches peak prevalence in those over 70. The male-to-female ratio is approximately 1.5:1, meaning men are somewhat more commonly affected, though women are not spared and may have a different distribution of sites.

A consistent and important epidemiological trend is the declining incidence of PDB over recent decades. Multiple studies from the UK, New Zealand, and other traditionally high-prevalence regions have demonstrated that both the frequency of new diagnoses and the severity of disease at diagnosis are decreasing compared to cohorts from the mid-twentieth century. Some researchers have proposed this parallels the widespread adoption of measles vaccination beginning in the 1960s, lending circumstantial support to a viral etiology hypothesis. However, the decline could also reflect dietary and environmental changes, ascertainment changes, or other factors.

Familial clustering is observed in roughly 15% of patients with PDB — first-degree relatives of an affected individual have approximately seven times the general population risk. This familial pattern provided the foundation for genetic discovery efforts that identified mutations in the SQSTM1 gene as a major susceptibility locus. Even among sporadic cases, however, genetic variants at several loci contribute meaningfully to risk.

Back to Table of Contents

Pathophysiology — Disordered Bone Remodeling

Normal bone remodeling is a tightly coupled, cyclical process. Osteoclasts resorb a discrete packet of old or damaged bone — a process taking approximately two weeks — after which osteoblasts fill the resorption cavity with new lamellar bone over a period of months. This coupling ensures that the volume and architecture of bone are precisely maintained throughout adult life. In Paget's disease, this coupling is disrupted at focal skeletal sites, resulting in a cascade of structural and metabolic consequences.

The primary pathological driver is osteoclast hyperactivity. Pagetic osteoclasts differ from their normal counterparts in several critical ways. They are dramatically enlarged — normal osteoclasts contain 3–20 nuclei, whereas pagetic osteoclasts can contain over 100 nuclei. They are excessively numerous, recruited to the affected bone in far greater numbers than normal. And they are hyperfunctional, generating a resorptive front that advances through bone at an abnormally rapid pace. This exuberant osteoclastic activity is visible on histology as enlarged resorption bays (Howship's lacunae).

In response to this excessive resorption, osteoblasts are recruited in large numbers and lay down new bone rapidly. However, the haste of bone formation means that the newly deposited matrix lacks the orderly parallel lamellae of normal bone. Instead, collagen fibers are laid down in random orientations, creating what pathologists describe as "woven bone." As this cycle repeats — areas of resorption followed by areas of disorganized deposition — the result is a characteristic histological pattern called a "mosaic" or "jigsaw puzzle" pattern, consisting of irregular cement lines outlining multiple packets of bone laid down at different times and in different directions.

The net result is paradoxical: the pagetic bone is larger and denser than normal bone on radiography, yet it is structurally weaker because its collagen architecture is disordered. The bone can bear compressive loads poorly, deforms under weight, bows in the tibial diaphysis, and fractures under stresses that normal bone would withstand. The enlarged, hypervascular bone also acts as an arteriovenous shunt — blood flows rapidly through the sinusoids of pagetic bone — contributing to elevated skin temperature over the affected site and, in severe polyostotic disease, a substantial increase in cardiac output that can precipitate high-output cardiac failure in patients with pre-existing heart disease.

Back to Table of Contents

Genetics and Etiology

The etiology of Paget's disease of bone is understood to involve a combination of genetic predisposition and environmental trigger(s), though the precise interplay remains under investigation. Genetic factors have been clarified considerably over the past two decades.

SQSTM1 mutations are the most important genetic finding. SQSTM1 encodes the p62 protein, a scaffold protein with multiple functional domains that acts as a signaling hub in the RANK–NF-κB pathway — the dominant signaling axis controlling osteoclast differentiation, activation, and survival. Heterozygous mutations in SQSTM1, particularly the P392L variant in the ubiquitin-binding domain, are found in 30–40% of patients with familial PDB and in approximately 5–10% of sporadic cases. These mutations do not abrogate p62 function entirely but instead sensitize osteoclast precursors to RANKL (receptor activator of NF-κB ligand), the key cytokine driving osteoclastogenesis. The result is exaggerated osteoclast activation in response to normal or even sub-threshold RANKL signals.

RANK and OPG pathway: Beyond SQSTM1, genome-wide association studies have identified susceptibility variants in TNFRSF11A (encoding RANK itself), TNFRSF11B (encoding osteoprotegerin, the decoy receptor that inhibits RANKL), and CSF1 (encoding colony-stimulating factor 1, which promotes osteoclast precursor proliferation). The convergence of multiple genetic loci on the RANK–RANKL–OPG axis underscores that PDB is fundamentally a disease of osteoclast dysregulation at the molecular level.

The paramyxoviral hypothesis emerged from the observation, made by electron microscopists in the 1970s and 1980s, that pagetic osteoclasts contain nuclear and cytoplasmic inclusion bodies resembling paramyxovirus nucleocapsids. Measles virus RNA sequences were detected in pagetic osteoclasts using in situ hybridization and RT-PCR in multiple studies, and canine distemper virus (another paramyxovirus) transcripts have also been reported. The epidemiological correlation between the decline in measles incidence (following vaccination programs initiated in the 1960s) and the subsequent decline in PDB prevalence is frequently cited as supporting circumstantial evidence.

However, the viral hypothesis remains controversial. Direct isolation of infectious virus from pagetic tissue has never been achieved. Several laboratories have been unable to reproduce the molecular viral detection results. Transgenic mice expressing mutant SQSTM1 develop a PDB-like phenotype without any viral exposure, demonstrating that the genetic defect alone can drive the disease. The current synthesis holds that SQSTM1 (and related pathway) mutations create the permissive genetic background, and an environmental factor — possibly but not definitively a paramyxoviral infection — acts as a second hit to trigger overt disease expression. Other proposed environmental factors include calcium deficiency in childhood, mechanical loading, and other viral agents.

Back to Table of Contents

Anatomical Sites

Paget's disease is notable for its site selectivity and asymmetric distribution. Unlike metabolic bone diseases such as osteoporosis, which affect the entire skeleton diffusely, PDB always begins in one or more discrete focal sites and typically does not extend beyond those sites once established (the "mosaic" region remains confined to the anatomical territory in which it first appeared).

The pelvis is the most commonly affected bone, involved in approximately 70% of symptomatic patients. Pelvic involvement may be asymptomatic but can cause hip pain through secondary osteoarthritis of the hip joint resulting from altered femoral head geometry. Lumbar vertebrae are the second most common site; pagetic vertebrae may enlarge sufficiently to cause spinal canal stenosis and nerve root compression. The proximal femur is frequently involved, and deformity of the femoral shaft contributes to the characteristic waddling gait and altered hip mechanics. The skull is involved in 25–40% of patients with polyostotic disease; extensive skull involvement produces the dramatic "cotton wool" radiographic appearance and may cause hearing loss, cranial nerve palsies, and basilar invagination. The tibia is the bone most visibly deformed in PDB — anterior bowing of the tibia, producing the so-called "saber tibia," results from weight-bearing on structurally weakened bone.

Disease may be classified as monostotic (single bone, approximately 35% of cases) or polyostotic (multiple bones, approximately 65%). Polyostotic disease is typically asymmetric — it does not follow the left-right symmetry seen in some other metabolic bone diseases. Small bones of the hands and feet are almost never affected. When PDB is found incidentally in a younger patient (<50 years), the possibility of SQSTM1 mutation is higher, and affected family members should be counseled about screening with ALP measurement.

An important radiological feature is that PDB progresses slowly within an affected bone. The lytic (resorptive) phase advances as a "blade of grass" or V-shaped lytic front along the shaft of a long bone, typically from the epiphysis toward the diaphysis. As the lytic front advances, the area behind it transitions to the mixed and then sclerotic phase. This predictable natural history within a bone means serial radiographs can document the rate of progression.

Back to Table of Contents

Clinical Presentation

The majority of patients with Paget's disease of bone — estimated at 65–75% — are entirely asymptomatic. The diagnosis is made incidentally, either because an alkaline phosphatase (ALP) level is found to be elevated on routine blood work, or because an X-ray obtained for another indication (such as evaluation of hip or back pain) reveals characteristic pagetic changes. This high proportion of subclinical disease means that epidemiological estimates of PDB prevalence from radiological surveys substantially exceed those based on clinical diagnosis rates.

When symptoms are present, bone pain is the most common complaint. Pagetic bone pain is characteristically deep and aching in quality. Unlike mechanical musculoskeletal pain, it may be present at rest and can be worse at night — a feature that sometimes raises concern for malignancy and warrants careful evaluation. The pain is felt directly in the affected bone and may be confused with arthritis when it occurs near a joint. Pain may also be referred — lumbar PDB may cause buttock or leg pain mimicking sciatica.

Bone deformity is a later manifestation that develops over years. The most visually striking deformity is enlargement of the skull — patients (or their families) may notice that hats no longer fit, or that hat size has gradually increased. Anterior bowing of the tibia produces a visible and palpable curve in the lower leg. Femoral involvement may cause bowing of the thigh or leg-length discrepancy. Vertebral enlargement and collapse may produce a kyphosis or loss of height.

Increased skin warmth over affected bone is a physical examination finding reflecting the hypervascular state of pagetic bone. A clinician can often feel warmth on palpation of a subcutaneous pagetic tibia or cranium. In polyostotic disease, systemic hypervascularization may cause a measurable increase in skin temperature and, in extreme cases, contribute to high-output cardiac failure.

Secondary osteoarthritis is a common complication in joints adjacent to pagetic bone. The hip is most frequently affected — pagetic deformity of the femoral head, acetabulum, or both alters the joint mechanics and accelerates cartilage wear. Secondary OA of the knee can occur with femoral or tibial involvement. This secondary arthritis is often the primary source of disability and may be the presenting complaint that ultimately leads to the PDB diagnosis.

Back to Table of Contents

Skull and Neurological Complications

Skull involvement in Paget's disease produces a distinctive and potentially serious set of neurological complications arising from two mechanisms: direct compression of neural structures within bony canals, and softening and deformation of the skull base under the weight of the calvarium.

Sensorineural hearing loss is the most common neurological complication of PDB and occurs through compression of the eighth cranial nerve (vestibulocochlear nerve) or its vascular supply within the internal auditory canal as the surrounding pagetic bone thickens and encroaches on this narrow passage. Hearing loss may be unilateral or bilateral, typically progressive, and may be accompanied by tinnitus and vestibular dysfunction. It is a common source of significant functional impairment and may begin subtly before frank hearing loss is apparent on audiometry.

Other cranial nerve palsies are less common but occur by the same compressive mechanism. The optic nerve (cranial nerve II) may be compressed as it passes through the optic canal — visual field defects, decreased visual acuity, or optic atrophy can result. The trigeminal nerve (V) involvement produces facial pain mimicking trigeminal neuralgia. Facial nerve (VII) palsy may cause ipsilateral facial weakness. Involvement of the lower cranial nerves (IX–XII) producing dysphonia, dysphagia, or tongue weakness can occur with severe skull base disease.

Basilar invagination (also called basilar impression) is the most serious skull complication. The skull base in severe PDB becomes softened and incompetent under the weight of the calvarium, allowing the odontoid process of the second cervical vertebra to invaginate upward into the foramen magnum. This progressively reduces the space available for the brainstem and can produce a constellation of findings including myelopathy, cerebellar ataxia, hydrocephalus (from obstruction of CSF flow at the foramen magnum), lower cranial nerve palsies, and in severe cases, respiratory failure from brainstem compression. Basilar invagination represents a true neurosurgical emergency when it causes progressive neurological deficit. The related deformity of platybasia (flattening of the skull base angle) may coexist.

Spinal cord and nerve root compression from pagetic vertebrae is another important source of neurological morbidity, particularly in the lumbar spine (cauda equina syndrome) and less commonly in the thoracic spine (spinal cord compression myelopathy). Pagetic vertebrae enlarge both anteroposteriorly and transversely, narrowing the spinal canal and neural foramina. Treatment with bisphosphonates to arrest bone hyperactivity is the first step; surgical decompression is reserved for significant neurological compromise not responding to medical management.

In the context of extensive skull involvement, leontiasis ossea — a lion-like appearance of the face from overgrowth of the facial bones and frontal bone — can develop, though this is a rare and advanced manifestation more often described in historical literature.

Back to Table of Contents

Skeletal Complications and Osteosarcoma

Fractures in Paget's disease occur through two mechanisms. First, the structural weakness of pagetic bone — enlarged but architecturally disordered — makes it vulnerable to chalk-stick fractures (also called banana fractures): transverse cortical fissures that appear as small horizontal lucent lines on the convex (tensile) side of a bowed long bone, visible on plain radiographs of the tibia or femur. These stress fractures may progress to complete fractures, which in pagetic bone tend to be transverse (perpendicular to the shaft) rather than the oblique or spiral pattern typical of normal bone fractures. Complete fractures of the femur and tibia are the most clinically significant and may require internal fixation complicated by the altered bone architecture and vascularity.

Second, pathological fracture may occur through weakened pagetic bone or, critically, through a site of malignant transformation. Any acute fracture in a known pagetic bone requires careful imaging evaluation to exclude underlying malignancy.

Secondary osteoarthritis, particularly of the hip and knee, is the most common cause of functional disability in PDB and has been discussed in the Clinical Presentation section. Total hip and knee arthroplasty in pagetic patients is technically more challenging than in osteoarthritis patients because of altered bone anatomy, increased vascularity (with greater intraoperative blood loss), and altered bone stock. Pre-operative bisphosphonate treatment to suppress disease activity before elective arthroplasty is standard practice and reduces intraoperative blood loss.

Osteosarcoma is the most feared complication of Paget's disease. Although it develops in fewer than 1% of all PDB patients, PDB is nevertheless the most common predisposing condition for osteosarcoma in adults over 60 — a demographic in whom osteosarcoma is otherwise rare. The mechanism is thought to involve the repeated cycles of DNA damage and repair in rapidly proliferating pagetic osteoblasts, which increase the probability of oncogenic mutations accumulating over time.

Pagetic osteosarcoma typically arises in patients aged 60–80 and presents with sudden, dramatic worsening of pain in a bone previously known to be pagetic. The pain is severe, constant, and often associated with rapid swelling or the appearance of a soft tissue mass. Radiographically, pagetic osteosarcoma shows features of aggressive malignancy superimposed on the pagetic background: cortical destruction, periosteal reaction (Codman's triangle, sunburst pattern), and soft tissue extension. Serum ALP may rise sharply above the patient's known pagetic baseline. The prognosis is extremely poor — median survival is approximately 12 months and the 5-year survival rate is approximately 5–10%, far worse than osteosarcoma arising in younger patients without PDB, largely because pagetic osteosarcoma patients are elderly with comorbidities and because the tumor often presents at an advanced stage. Any patient with known PDB who reports a sudden change in the character or severity of bone pain must be urgently evaluated with imaging and, if malignancy is suspected, biopsy.

High-output cardiac failure is a rare but serious systemic complication of severe polyostotic PDB. The hypervascular pagetic bone acts as a large arteriovenous shunt, diverting blood rapidly through the skeletal circulation without adequate oxygen extraction. In patients with extensive polyostotic disease, this can increase cardiac output substantially — by 20–40% in some series. In patients with pre-existing cardiac disease (coronary artery disease, cardiomyopathy, valvular disease), this additional circulatory demand may precipitate or worsen heart failure. In patients with normal hearts, the heart eventually compensates but may hypertrophy over time. Treatment with bisphosphonates suppresses pagetic bone activity and, over months, reduces the hypervascular state and cardiac burden.

Back to Table of Contents

Laboratory and Imaging Diagnosis

Serum alkaline phosphatase (ALP) is the cornerstone laboratory test for PDB. Bone-specific ALP, produced by active osteoblasts, is elevated in virtually all patients with active symptomatic disease. In extensive polyostotic disease, total ALP may be five to ten times the upper limit of normal — among the highest ALP values encountered in clinical medicine outside of hepatobiliary disease. The bone-specific ALP isoform can be measured separately and is more specific for skeletal activity than total ALP, but total ALP is adequate for initial evaluation when liver disease is excluded. ALP is used both for diagnosis and for monitoring treatment response — successful bisphosphonate therapy reduces ALP toward normal over 3–6 months. Normal ALP in a patient with radiologically confirmed PDB implies quiescent or burned-out disease that may not require treatment.

Serum calcium and phosphate are characteristically normal in PDB — a key distinguishing feature from primary hyperparathyroidism (elevated calcium) and osteomalacia (low phosphate or calcium). The one exception is immobilization: if a patient with extensive polyostotic PDB is immobilized (e.g., after fracture or surgery), the suppression of osteoblast activity while osteoclast activity continues can release calcium into the bloodstream faster than the kidneys can excrete it, causing hypercalcemia of immobilization. This is a recognized risk requiring monitoring.

Bone turnover markers including N-telopeptide (NTX) and C-telopeptide (CTX) of type I collagen in urine or serum reflect bone resorption activity and are sometimes used as supplementary markers, particularly when ALP may be confounded by liver disease. Urinary hydroxyproline was used historically but has been superseded by more specific assays.

Plain radiography remains central to diagnosis, site mapping, and monitoring for complications. Characteristic radiographic features include: bone expansion with cortical thickening; mixed lytic and sclerotic areas; coarsened trabecular pattern; and specific patterns depending on the phase of disease. The lytic phase in the skull produces a geographic area of bone loss called osteoporosis circumscripta — a sharply demarcated area of decreased density with a flame-shaped or wedge-shaped leading edge. In long bones, the advancing lytic front has the characteristic "blade of grass" or "V-shaped" appearance. The sclerotic phase produces the "cotton wool" appearance in the skull and "ivory vertebra" in the spine. Vertebral enlargement ("picture frame vertebra" with dense peripheral sclerosis and central lucency) is characteristic. Bowing deformities and chalk-stick fractures are visible on long bone views.

Bone scintigraphy (technetium-99m methylene diphosphonate bone scan) is exquisitely sensitive for active PDB — pagetic lesions appear as intensely hot uptake that reflects the high bone turnover. Bone scan is the most useful test for mapping the full extent of PDB at diagnosis (to determine whether disease is monostotic or polyostotic) and to identify sites that were not suspected clinically. A bone scan does not distinguish PDB from metastatic disease or fracture, so positive findings require radiographic correlation.

MRI is not routinely used for the diagnosis of uncomplicated PDB. Its principal role in this condition is to evaluate neurological complications — spinal canal stenosis, basilar invagination, or cranial nerve canal compromise — where its soft-tissue resolution surpasses plain CT. MRI is also essential in the evaluation of suspected osteosarcomatous transformation, where it delineates the extent of soft-tissue extension and marrow involvement necessary for staging.

CT is helpful for characterizing complex anatomy, particularly skull base deformities and spinal stenosis, and for surgical planning before orthopedic or neurosurgical procedures on pagetic bone.

Back to Table of Contents

Treatment — Bisphosphonates

The modern treatment of Paget's disease of bone centers on bisphosphonates, a class of drugs that potently inhibit osteoclast activity. Bisphosphonates are pyrophosphate analogues that bind avidly to hydroxyapatite in bone — particularly at sites of high bone turnover — and are then internalized by osteoclasts during resorption, where they inhibit the mevalonate pathway enzyme farnesyl pyrophosphate synthase, ultimately causing osteoclast apoptosis and suppression of bone resorption. With osteoclast activity suppressed, the coupled osteoblast response also diminishes, ALP falls, and the chaotic bone remodeling of PDB is brought under control.

Indications for treatment are not universally agreed upon, but established indications include: bone pain attributable to PDB (not to secondary OA); high-risk anatomical sites regardless of symptoms (skull, vertebrae adjacent to spinal cord, weight-bearing bones near joints); neurological complications (hearing loss progression, cranial nerve involvement, impending basilar invagination); markedly elevated ALP (more than three times the upper limit of normal); before elective orthopedic surgery on pagetic bone to reduce vascularity and blood loss; and in young patients to potentially slow disease progression. Asymptomatic patients with mildly elevated ALP and no high-risk features may be managed with watchful waiting and periodic monitoring.

Zoledronic acid (5 mg intravenously as a single infusion over 15 minutes) is the most effective bisphosphonate for PDB and is now considered first-line therapy. The landmark ZIPP (Zoledronate in Paget's disease) randomized controlled trial (Reid et al., 2005) demonstrated that a single infusion of zoledronic acid achieved biochemical remission (ALP normalization) in approximately 89% of patients, compared with only 58% with daily oral risedronate. The treatment effect of a single zoledronic acid infusion is remarkably durable — remission lasting 5–6 years or longer has been documented in follow-up studies, and many patients achieve sustained normalization without retreatment. Common side effects include a transient flu-like reaction (fever, myalgia, arthralgia) in the 24–72 hours following infusion — the "acute phase response" — which is mediated by the same mevalonate pathway inhibition that causes osteoclast apoptosis and is self-limiting. Osteonecrosis of the jaw (ONJ) is a rare complication associated primarily with much higher doses and longer courses used in oncology, not with single-dose PDB treatment, but good oral hygiene and avoidance of dental procedures immediately surrounding the infusion is standard advice.

Oral bisphosphonates remain alternatives when intravenous treatment is not feasible or desired. Risedronate 30 mg once daily for 2 months achieves biochemical remission in approximately 73% of patients. Alendronate 40 mg once daily for 6 months is similarly effective but requires a longer treatment course. Oral bisphosphonates must be taken on an empty stomach with a full glass of water, and the patient must remain upright for at least 30 minutes afterward, to minimize the risk of esophageal irritation — a practical limitation for elderly or mobility-impaired patients.

Calcium and vitamin D supplementation is required during bisphosphonate treatment for PDB. Suppressing osteoclast activity without adequate substrate for mineralization of the newly formed bone can precipitate hypocalcemia, particularly in patients who are vitamin D deficient. Standard supplementation of 1,000–1,500 mg elemental calcium daily and 800–1,000 IU vitamin D3 daily is recommended throughout bisphosphonate treatment and for several months afterward. Serum calcium should be checked before starting bisphosphonate therapy, and pre-existing hypocalcemia must be corrected first.

Pain management: NSAIDs provide effective relief of mild to moderate pagetic bone pain and can be used while awaiting the full benefit of bisphosphonate therapy (which develops over weeks to months). For patients in whom NSAIDs are contraindicated (renal impairment, cardiovascular disease, GI risk), acetaminophen or tramadol may be used.

Monitoring response to treatment: Serum ALP is measured 3 months after completing bisphosphonate therapy to assess biochemical response. ALP normalization is the goal. If ALP remains more than twice the upper limit of normal and the patient is symptomatic, retreatment should be considered. Routine bone scan is not needed for monitoring — follow clinical symptoms and ALP. ALP is then measured annually to detect biochemical relapse, defined as ALP rising again above normal or above 25% of the pretreatment value. The very long remission achievable with zoledronic acid means many patients require only a single lifetime treatment.

Orthopedic surgery: Total hip or total knee arthroplasty is indicated for severe secondary osteoarthritis not adequately managed with medical therapy — the same indications as for primary OA, with the caveat that pre-operative bisphosphonate treatment (ideally at least 3 months before elective surgery) reduces intraoperative blood loss. Tibial osteotomy may be considered for severe anterior bowing causing significant functional impairment, though this is uncommon. Neurosurgical decompression (laminectomy, posterior fossa decompression for basilar invagination) is reserved for progressive neurological deficit not responsive to medical treatment.

Back to Table of Contents

Key Research Papers

  1. Siris ES, et al. Paget's disease of bone. N Engl J Med. 2006;355(6):593–600. PMID: 16899778
  2. Lowe C, et al. Bisphosphonate therapy for Paget's disease of bone. Cochrane Database Syst Rev. 2013;(7):CD004956. PMID: 23836315
  3. Helfrich MH, et al. Measles virus nucleocapsid transcripts are detected in pagetic bone but not in normal bone. J Bone Miner Res. 1997;12(8):1298–306. PMID: 9258757
  4. Ralston SH, et al. SQSTM1 mutations in familial and sporadic Paget's disease of bone. J Bone Miner Res. 2008;23(7):1002–9. PMID: 18416681
  5. Reid IR, et al. Randomized trial of zoledronate in Paget's disease of bone. N Engl J Med. 2005;353(9):898–908. PMID: 16135834
  6. Langston AL, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int. 2007;80(1):1–9. PMID: 17205221
  7. Michou L, et al. Genetics of Paget's disease of bone. Joint Bone Spine. 2006;73(3):243–8. PMID: 16600662
  8. Falchetti A, et al. Genetics of Paget's disease of bone. J Bone Miner Metab. 2006;24(2):99–110. PMID: 16502111
  9. Singer FR. The etiology of Paget's disease of bone: viral hypothesis revisited. J Bone Miner Res. 2013;28(2):244–8. PMID: 23234637
  10. Tan A, et al. Declining incidence of Paget's disease in Scotland. J Bone Miner Res. 2017;32(3):523–527. PMID: 27736017
  11. Cascorbi I. Bisphosphonates in Paget's disease of bone. Expert Rev Clin Pharmacol. 2013;6(1):3–9. PMID: 23272787
  12. Wermers RA, et al. Clinical presentation of Paget's disease. Mayo Clin Proc. 2007;82(6):754. PMID: 17550756

Back to Table of Contents

PubMed Research Searches

Back to Table of Contents

Connections

Back to Table of Contents